Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc demonstrates a strong potential for growth through its ongoing development of innovative treatments for diabetes and obesity, showcasing favorable clinical results for its lead candidate, icovamenib, which achieved a statistically significant reduction in HbA1c levels over a 52-week study period. The company continues to advance its pipeline, with the initiation of Phase I trials for BMF-650, an investigational oral GLP-1 receptor agonist that has shown promising preclinical results in weight reduction and glucose control. Additionally, Biomea Fusion's improved financial performance, indicated by a reduced net loss of $16.4 million for Q3 2025 compared to $32.8 million in Q3 2024, reflects efficient resource management and bolsters confidence in the company's future prospects.

Bears say

Biomea Fusion Inc. has reported a decrease in research and development expenses, falling from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may indicate a reduction in its investment in clinical trials and product development. General and administrative expenses also decreased from $6.8 million to $4.2 million during the same period, suggesting potential cost-cutting measures. Consequently, the company's revised price target reflects a downward adjustment from $16.00 to $12.00, raising concerns about its financial trajectory and growth potential.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.